Researchers identify increased brain tumor risk with specific contraceptive use

Share this article J&J’s Tremfya is forecast to generate $6.5bn in sales in 2030, according to GlobalData. Credit: Michael Vi via Shutterstock. Johnson & Johnson

Bris­tol My­ers Squibb is go­ing glob­al to chron­i­cle the re­al world pso­ri­a­sis ex­pe­ri­ences of physi­cians and pa­tients, specif­i­cal­ly high­light­ing the chal­lenges for peo­ple of col­or.